Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Sava Infond d.o.o.

Sava Infond d.o.o. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,180 shares of the biopharmaceutical company’s stock after acquiring an additional 100 shares during the quarter. Sava Infond d.o.o.’s holdings in Alnylam Pharmaceuticals were worth $711,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $27,000. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $42,000. Washington Trust Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 61 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 87 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of ALNY stock opened at $456.35 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The stock has a fifty day moving average of $441.57 and a two-hundred day moving average of $338.75. The firm has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the firm posted ($0.13) EPS. The firm’s quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $570.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 2nd. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a report on Friday, August 1st. Evercore ISI boosted their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a report on Thursday, September 11th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $439.58.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Colleen F. Reitan sold 18,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director owned 775 shares of the company’s stock, valued at $362,390. This trade represents a 95.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.